Together with investigators at Oncode and group leaders at the Netherlands Cancer Institute, Shridar Ganesan, MD, PhD, chief of molecular oncology, associate director for translational research, and Omar Boraie Chair in Genomic Science at Rutgers Cancer Institute found new opportunities to improve diagnostics and targeted therapy for many cancer patients. The team explored genetic alterations in the Fibroblast Growth Factor Receptor 2 (FGFR2) gene, which contributes to the formation of tumors. Their findings, published in the online version of Nature (DOI: 10.1038/s41586-022-05066-5), lay the groundwork for development of clinical trials aimed at rationally increasing the number of patients who will benefit from FGFR inhibitor therapy. Learn more |